QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:NTLA

Intellia Therapeutics - NTLA Stock Forecast, Price & News

$64.17
-4.25 (-6.21%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$63.79
$68.38
50-Day Range
$38.49
$71.70
52-Week Range
$37.08
$180.59
Volume
995,310 shs
Average Volume
1.21 million shs
Market Capitalization
$4.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$128.00

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
99.5% Upside
$128.00 Price Target
Short Interest
Healthy
9.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.85mentions of Intellia Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.83) to ($5.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

115th out of 1,124 stocks

Diagnostic Substances Industry

2nd out of 18 stocks

NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics Trading Down 6.2 %

Shares of Intellia Therapeutics stock traded down $4.25 on Tuesday, reaching $64.17. 995,310 shares of the company were exchanged, compared to its average volume of 1,214,870. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of -11.99 and a beta of 2.00. Intellia Therapeutics has a one year low of $37.08 and a one year high of $180.59. The company has a 50-day moving average of $58.13 and a 200 day moving average of $63.14.

Intellia Therapeutics (NASDAQ:NTLA - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 40.23%. The firm had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. During the same quarter in the prior year, the business earned ($1.01) EPS. The business's revenue was up 115.4% compared to the same quarter last year. Analysts predict that Intellia Therapeutics will post -5.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NTLA shares. Chardan Capital cut their target price on Intellia Therapeutics from $172.00 to $146.00 and set a "buy" rating on the stock in a research note on Friday, August 5th. Credit Suisse Group lifted their price target on shares of Intellia Therapeutics to $101.00 in a research report on Tuesday, August 9th. The Goldman Sachs Group lowered their price objective on shares of Intellia Therapeutics from $206.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, August 5th. Finally, JMP Securities lowered their price target on Intellia Therapeutics from $165.00 to $110.00 in a report on Monday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $128.00.

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Intellia Therapeutics (NASDAQ:NTLA) PT Raised to $101.00
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Why Intellia Therapeutics Stock Is Sinking Today
Is It Time to Buy the Dip With Biotech Stocks?
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$128.00
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+99.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$-267,890,000.00
Net Margins
-883.17%
Pretax Margin
-883.17%

Debt

Sales & Book Value

Annual Sales
$33.05 million
Book Value
$14.15 per share

Miscellaneous

Free Float
73,048,000
Market Cap
$4.88 billion
Optionable
Optionable
Beta
2.00














NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2022?

16 Wall Street research analysts have issued twelve-month price targets for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $54.00 to $182.00. On average, they predict the company's share price to reach $128.00 in the next twelve months. This suggests a possible upside of 99.5% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2022?

Intellia Therapeutics' stock was trading at $118.24 at the start of the year. Since then, NTLA shares have decreased by 45.7% and is now trading at $64.17.
View the best growth stocks for 2022 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by $0.03. The firm had revenue of $14 million for the quarter, compared to analyst estimates of $9.50 million. Intellia Therapeutics had a negative net margin of 883.17% and a negative trailing twelve-month return on equity of 40.23%. The company's revenue was up 115.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.01) EPS.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.54%), FMR LLC (4.35%), State Street Corp (4.14%), Sumitomo Mitsui Trust Holdings Inc. (3.67%), Nikko Asset Management Americas Inc. (3.67%) and Price T Rowe Associates Inc. MD (2.69%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $64.17.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $4.88 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 485 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.